Ilyang Pharmaceutical일양약품
007570 · KOSPI · ₩007570 · 일양약품
- Market cap
- ₩133B
- Enterprise value
- ₩224B
- P/E
- 7.7×
- P/B
- 0.5×
- Dividend yield
- 2.5%
- ROE
- 6.8%
- Net margin
- 6.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−57.0% from the high
₩6,750Today: ₩6,990 – ₩7,130₩16,240
Returns
- 1W−1.5%
- 1M−9.5%
- 3M−15.5%
- 6M−38.6%
- YTD−52.1%
- 1Y−52.1%
- Volume today
- 9,644
- 0.4× the 20-day average
- Traded today
- ₩68M
- Listed shares
- 19,085,664
- EPS (12 months)
- ₩906
- Earnings yield 13.0%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 31 of 100 (50 is a normal day for this stock).
- MomentumWeak-10.5% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Ilyang Pharmaceutical stock overview
Ilyang Pharmaceutical (일양약품, KRX: 007570) is listed on KOSPI, in the Biotech & Pharma sector. Ilyang Pharmaceutical is a South Korean pharmaceutical company that, together with its subsidiaries Ilyang Biopharm, Kantech and Ilyang Pharmaceutical (Jilin), develops and sells prescription and over-the-counter medicines, health supplements, and influenza vaccines. Its shares closed at ₩6,990 on Oct 27, 2026, down 1.41% on the day, giving it a market value of ₩133B.
Key facts
- Market cap
- ₩133B
- Sector
- Biotech & Pharma
- Latest price change
- −1.41%
- As of
- Oct 27, 2026
- Main business
- Ilyang Pharmaceutical is a South Korean pharmaceutical company that, together with its subsidiaries Ilyang Biopharm, Kantech and Ilyang Pharmaceutical (Jilin), develops and sells prescription and over-the-counter medicines, health supplements, and influenza vaccines.
Quick answers about Ilyang Pharmaceutical
- What does Ilyang Pharmaceutical do?
- Ilyang Pharmaceutical is a South Korean pharmaceutical company that, together with its subsidiaries Ilyang Biopharm, Kantech and Ilyang Pharmaceutical (Jilin), develops and sells prescription and over-the-counter medicines, health supplements, and influenza vaccines. Its main products include the anti-ulcer drug Naltec, the leukemia treatment Shupect (raltitrexed-based, marketed as Ludotinib in some references), and a line of influenza vaccines produced at its Eumseong plant. Naltec is exported to Mexico and four other countries, and the company also provides software and ERP services through its Kantech subsidiary.
- What is the market cap of Ilyang Pharmaceutical?
- The market capitalisation of Ilyang Pharmaceutical was ₩133B at the close on Oct 27, 2026.
- Who are the largest shareholders of Ilyang Pharmaceutical?
- According to the latest official filings, the largest reported holders are Jeong Yu-seok (27.04%, as of Sep 23, 2026); National Pension Service (0.43%, as of Dec 31, 2025); EMERGING MARKETS CORE EQUITY 2 PORTFOLIO (0.36%, as of Jul 31, 2026).
- When is the next earnings report from Ilyang Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when Ilyang Pharmaceutical filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own Ilyang Pharmaceutical?
- Yes. The National Pension Service held 0.43% of Ilyang Pharmaceutical shares as of Dec 31, 2025.
Company profile
Ilyang Pharmaceutical is a South Korean pharmaceutical company that, together with its subsidiaries Ilyang Biopharm, Kantech and Ilyang Pharmaceutical (Jilin), develops and sells prescription and over-the-counter medicines, health supplements, and influenza vaccines. Its main products include the anti-ulcer drug Naltec, the leukemia treatment Shupect (raltitrexed-based, marketed as Ludotinib in some references), and a line of influenza vaccines produced at its Eumseong plant. Naltec is exported to Mexico and four other countries, and the company also provides software and ERP services through its Kantech subsidiary. The company operates primarily in South Korea, with export sales to overseas markets including China through a technology transfer arrangement.
Written by AI from the company's latest annual report.
- Korean name
- 일양약품
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 정유석
- Founded
- Jul 1946
- Listed
- Aug 1974
- Listed shares
- 19,085,664
- Fiscal year ends
- Month 12
- Website
- www.ilyang.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- [Amended] Designation as Insincere Disclosure CompanyOct 8, 2026
- Designation as Company for Unfaithful DisclosureOct 7, 2026
- Change in largest shareholder's holdingsSep 23, 2026
- 5%+ holding reportSep 23, 2026
- 5%+ holding reportSep 23, 2026
Titles in Korean until English translations are added.
Also known as: Ilyang Pharmaceutical / 일양약품 / 007570 / KRX:007570
Source: KRX statistical information